Guide for Authors

  • All journal information and instructions compiled in one document (PDF) in just one mouse-click Author information pack

    BEFORE YOU BEGIN
    • Ethics in publishing
    • Human and animal rights
    • Conflict of interest
    • Submission declaration
    • Changes to authorship
    • Reporting clinical trials
    • Copyright
    • Role of the funding source
    • Funding body agreements and policies
    • Language (usage and editing services)
    • Submission
    PREPARATION
    • Double-blind review
    • Use of word processing software
    • Article structure
    • Essential title page information
    • Abstract
    • Level of Clinical Evidence
    • Keywords
    • Abbreviations
    • Acknowledgements
    • Units
    • Artwork
    • Tables
    • References
    • Video data
    • Supplementary data
    • Submission checklist
    AFTER ACCEPTANCE
    • Use of the Digital Object Identifier
    • Proofs
    AUTHOR INQUIRIES

    Ethics in publishing

    For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

    Human and animal rights

    If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.html; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

    Conflict of interest

    All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

    Submission declaration

    Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

    Changes to authorship

    This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
    Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.
    After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

    Reporting clinical trials

    Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on http://www.consort-statement.org.

    Copyright

    Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see http://www.elsevier.com/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
    Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.

    Retained author rights
    As an author you (or your employer or institution) retain certain rights; for details you are referred to: http://www.elsevier.com/authorsrights.

    Return signed agreements to D. Scot Malay, DPM, MSCE, FACFAS, via email (editorjfas@gmail.com), facsimile (215-967-4463), or standard mail (2314 Waverly Street, Philadelphia, PA 19146).

    Financial Disclosure and Conflict of Interest Statement
    Every author, including the corresponding author and all co-authors, must submit a signed conflict of interest statement to the Journal office, at the time of submission of a manuscript for editorial consideration. In this form, authors should disclose any financial arrangements they may have with any company whose product is pertinent to the submitted manuscript, or with a company making a competing product. The Every author, including the corresponding author and all co-authors, must submit a signed conflict of interest statement to the Journal office, at the time of submission of a manuscript for editorial consideration. In this form, authors should disclose any financial arrangements they may have with any company whose product is pertinent to the submitted manuscript, or with a company making a competing product. The information will be held in confidence while the paper is under review and will not influence the blind peer review process. If the article is accepted for publication, a disclosure statement will appear with the article. The conflict of interest statement can be downloaded the “Author’s Corner” section of the JFAS webpage (www.jfas.org/). The completed and signed statement/s can be returned to D. Scot Malay, Editor, JFAS, via electronic mail (after scanning the completed and signed statement/s) at editorjfas@gmail.com, via telefax at (215) 967-4463, or via standard mail at 2314 Waverly Street, Philadelphia, PA 19146, USA. No manuscript can be published without first having the conflict of interest disclosures on file in the Journal office.

    Role of the funding source

    You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

    Funding body agreements and policies

    Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

    Language (usage and editing services)

    Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

    Submission

    Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

    Submit your article
    Please submit your article via http://www.jfas.org.

    Double-blind review

    This journal uses double-blind review, which means that both the reviewer and author name(s) are not allowed to be revealed to one another for a manuscript under review. The identities of the authors are concealed from the reviewers, and vice versa. For more information please refer to http://www.elsevier.com/reviewers/peer-review. To facilitate this, please include the following separately:
    Title page (with author details): This should include the title, authors' names and affiliations, and a complete address for the corresponding author including telephone and e-mail address.
    Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any Acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

    Use of word processing software

    It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.
    To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

    Article structure

    Types of Manuscripts and Articles
    Original Research—scientific reports of clinical and laboratory investigations, including randomized controlled trials, cross-over experiments, meta-analyses, prospective and retrospective cohort (N greater than or equal to 30) studies, case control studies, analyses of secular trends, and cross sectional studies.

    Review Article—including systematic reviews and narrative review articles. Case Report—observational reports of rare diseases or unusual interventions, ranging from a single case to a series (N less than or equal to 30) of patients.

    Instructional Course—a detailed description of a specific intervention or diagnostic test, accompanied by detailed figure images and video add-ons available at the JFAS Website.

    Tips, Quips and Pearls—a brief and practical description of a useful clinical or surgical maneuver or procedure, accompanied by useful figure images.

    Editorial or Commentary—an article expressing an opinion about a topic considered interesting to foot and ankle surgeons

    Letter to the Editor—a letter from a reader expressing an opinion or raising a question, usually focusing on a particular published article, and usually accompanied by a reply from the author/s of the original article.

    Manuscript Templates
    Authors are instructed to download and use the appropriate manuscript template/s (Original Research; Review; Case Report; Tips, Quips, and Pearls; and Title Page), which can be found in the “Author Information” list of menu options, under “JFAS Manuscript Template files” at the sign-in page (http://ees.elsevier.com/jfas/default.asp). Paying attention to the template/s should enable an author to provide all of the manuscript elements required for publication. Manuscripts are commonly submitted without all of the required information, or with information misplaced in the document, and the manuscript templates were developed in an effort to guide authors through the manuscript preparation process without omitting or misplacing required information. Following the template should minimize critical appraisal points that require authors to further revise their manuscript. The templates are meant to guide manuscript production, without telling the author what to say or how to interpret findings. If a manuscript is not in compliance with the content and formatting guidelines defined in the appropriate manuscript template/s, and if it is not in compliance with the items defined herein (in the Guide for Authors), we will not be able to further consider or publish the manuscript. Therefore, authors are advised to pay attention to the information in the Guide for Authors and the appropriate Manuscript Template/s. Combining the information in the manuscript template with that in the Guide for Authors should cover almost every element that is required for publication, assuming that the content matter is appropriate for JFAS.

    Manuscript Format
    The following details pertain to the different types of manuscripts published in JFAS. Each page should be numbered consecutively, in the bottom right corner, with the title page designated as page 1. The manuscript should also be double-spaced, line-numbered, and left margin justified. The contents of your manuscript should include the following segments in the following order:

    Original Research or Review Article
    (1) Title, (2) Abstract, (3) Level of Clinical Evidence, (4) Key Words, (5) Text: Introduction, Patients/Materials and Methods, Results, Discussion (6) Acknowledgments, (7) References, (8) Tables, (9) Figures, (10) e-only electronic add-ons, which are made available to readers at the jfas.org website.

    Instructional Course or Tips, Quips and Pearls
    (1) Title, (2) Abstract, (3) Key Words, (4) Text: Introduction, Surgical Technique, Discussion, (5) Acknowledgments, (6) References, (7) Tables, (8) Figures, (9) e-only electronic add-ons, which are made available to readers at the jfas.org website.

    Editorial, Commentary, or Letter to the Editor
    (1) Title, (2) References, (3) Tables, (4) Figures, (5) ) e-only electronic add-ons, which are made available to readers at the jfas.org website.

    General Rules
    The main segments are to be identified by bold, left-margin headings, capitalizing the first letter of the first word of each named section. Subheadings, if needed, should be in non-bold italic font, left-margin aligned, capitalizing the first letter of the first word of the subheading.

    As a general rule, when describing activities that were part of the investigation, as well as the observed outcomes, use the past tense. Present tense is reserved for discussions of states of knowledge, which are considered ongoing (for example, “Open reduction and internal fixation is the treatment of choice for displaced, unstable fractures…”).

    Whenever uncertainty arises in regard to format, authors are encouraged to consult the following text: AMA Manual of Style: A Guide for Authors and Editors, 10th Edition.

    Introduction
    State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

    Material and methods
    Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

    Patients and Methods versus Materials and Methods
    If the study is a clinical investigation involving human participants, use the heading "Patients and Methods." If the study involves animals, cadavers, or in vitro or computer models of any sort, use the heading "Materials and Methods." In general, the Methods section should describe the following elements of the investigation: (1) Aims; (2) Study population; (3) Assessors and other members of the investigational team, population, or sample; (4) Intervention; (5) Endpoints (outcomes); (6) Statistical methods used to determine the meaning of the results

    The Building Blocks of Good Clinical Evidence
    (1) Explicitly defined research question, population, and endpoints; (2) Randomized treatment allocation and intention-to-treat analysis; (3) Participatns and outcomes assessors blind to treatmnet allocation; (4) use of a valid health measurement (quality of life) instrument; (5) Poswer and sample size determined a priori; (6) Statistical analyses compatible with type and sdistrubiton of the data; (7) Point estimate and 95% confidence interval reported (From Turlick MA, Kushner D, Stock D. J Am Podiatri Med Assoc 93:392-398, 2003.

    Assessors
    Describe members of the investigational team in regard to their participation in the study: (1) If they served as outcome assessors. (2) If they performed an intervention. (3) If they abstracted data from medical records, in the case of a retrospective study.

    For studies in which subjective measurements are determined, such as measurements of radiographic angles, describe the method for breaking ties and determining an outcome when indecision or uncertainty exists.

    If outcomes assessors were blind to treatment allocation, state this.

    If outcomes assessors were participants in the intervention, such as members of the surgical team or treating clinicians, state this.

    Study Population
    The Methods section provides readers with an explicit description of the participant/patient population and the time period from which they were selected. The time period should delineate the month, day, year that the period started and the day, month, and year that the period ended (MM/DD/YYYY-MM/DD/YYYY). If the specific day is not know, it is acceptable to just use the month.

    For Case Reports and Series and Cohort Studies, state whether or not the participants were enrolled consecutively, and clearly indicate inclusion and exclusion criteria.

    Refer to subjects as "participants" if the diagnostic test or intervention is experimental and not yet approved for use by the US FDA. Refer to participants as "patients" for all other tests or interventions that are already known to be therapeutic, safe, and efficacious.

    Intervention
    Explicitly describe the intervention in any investigation.

    If participants were randomized to an active therapy that was compared to standard therapy or to a placebo, you must describe each treatment arm.

    Avoid presenting a detailed narrative report of an operative intervention for a standard procedure. Instead, cite a reference for that standard procedure. Describe variations on the procedure.

    Thoroughly describe all novel interventions, notable variations on standard procedures, decision points related to an intervention, and adjunct procedures.

    Use generic drug names where possible. When a brand name is used, include the name, city, state, country of the manufacturer in parentheses imeediately after the proprietary name. Whenever medication use is described, proivde complete dosing information: dose, method of administration, frequency of use, duration of use.

    Endpoints (Outcomes)
    Explicitly define outcome measures in terms of (1) how the variable was measured, (2) who made the measurement, and (3) whether or not the assessor was blind to the interventional (for an intervention trial).

    Clearly state if outcomes were based on physical examination, chart review, telephone interview, questionnaire, radiographic films, or some other method.

    Consider for analysis any variable that you consider to be important in regard to the treatment of patients, as it pertains to the investigation

    "Hard" endpoints such as analytical measurements, clinical and microbiology laboratory results, and other specific measurements are preferred to "soft" endpoints. If "soft" endpoints such as quality of life (QOL) or foot-related QOL are used, it is preferred that health measurement instruments that have been previously shown to be reliable and provide valid information be used.

    A health measurement insturment is not in and of itself valid, although the information gained from the use of the health measureemnt instrument should be used. QOL instruments should be specific to the foot and ankle (e.g., ACFAS, AOFAS, Bristol Foot Score, Foot Function Index).

    Describe an investigator-derived questionnaire in terms of reliability and validity if such testing was undertaken by the investigators or if the questionnaire has been described in a previous publication.

    For scales that rank categories (e.g., mild, moderate, severe), use an aggregate score. For measurements of pain, the 10-cm visual analog scale (VAS) is recommended.

    Statistical Methods
    Clearly describe the statistical plan. Include, at minimum, descriptive and inferential statistical analyses. Ideally, also include univariate and multiple variable statistical analyses.

    In the descriptive statistical analysis, define parameters such as the measure of central tendency (mean or median average) and measures of dispersion (standard deviation or range).

    Select the parameter, as well as the statistical test, based on the type and distribution of data.

    Continuous numeric data that are normally distributed are suitable for representation using the mean and standard deviaion and may be analyzed using mean-based statistical tests such as Student's t test.

    Categorical data and data that are non-normally distributed are suitable for representation using the median and range and may be analyzed using median-based (nonparametric) methods such as the Wilcoxon matched-pairs signed-ranks test, sign test, Wilcoxon rank-sum test, and the Kruskal-Wallis equality-of-populations rank test and other null hypotheseis tests and methods of estimation.

    Use univariate analyses to describe the association of independent variables with the outcome of interest (dependent variable). Use multiple variable analyses to describe the association of all of the clinically important variables with the outcome of interest.

    Present results with only as much precision as is of scientific value. For example, report measures of association (e.g., odds ratios, relative risks, risk differences) to 2 significant digits. Reserve the terms significant and significantly for when describing statistical differences. Do not make the statement "no significant difference was found" between 2 or more groups unless a power analysis was done and the value of alpha (level osf significance typically 5% or p value < .05) or beta (the power to detect a statistically significant difference, usually 80% or 90%) is reported. Denote the probability of the null hypothesis using a lowercase italic p separated from the word "value" by a hyphen (specifically p value.

    Use of the word “significant” requires reporting of a p value (probability) or, preferably, the 95% confidence interval about a point estimate. 95% confidence intervals are preferred whenever the results of survivor analyses are given in the text, tables, or graphs. Except when 1-sided tests are required by study methodology, such as in noninferiority trials, 2-sided p values should be reported. By convention, Report p values > .01 to 2 decimal places, p values between .01 and .001 to 3 decimal places, and p values < .001 as p <.001. Probabilities should never be reported as p = .000. Furthermore, use of the word “correlation” or the phrase “correlates with” requires that a correlation coefficient be calculated and reported, otherwise terms such as “association” or “associated” should be used.

    Registered Trademarks and Copyrights
    Generic names are preferred.

    · Any and every time that a proprietary substance (such as a medication), device, equipment, or software program is mentioned in the manuscript, it must be accompanied by either of the following symbols: “®” or “™”, indicating that the substance or device is a registered trademark.

    · It is advisable to avoid using proprietary terms in the title of the manuscript.

    · The following information must be provided in parentheses, immediately following mention of the proprietary item: proprietor’s name (the name of the company that owns the registered trademark), city and state wherein the proprietor’s headquarters are located, and the country if other than the United States.

    · Authors should use the proprietor’s precise terminology (exact name and registered trademark symbol, “®” or “™”) when referring to a specific proprietary substance, device or procedure. If copyrighted material is mentioned, then the “©” symbol should accompany the item; if it is trademarked, then either the “®” or the “™” symbol should be used, in accordance with the owner’s preference. This information is usually available at the proprietor’s Web site.

    · The use of copyrighted material requires that the author obtain explicit permission from the owner of the copyright (publisher), and the author, for such use.

    The results of a sensitivity analysis, such as that described by Greenland (Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Amer J Epidemiol. 1993; 138: 923–936.), or that described by Rosenbaum (Rosenbaum PR. Sensitivity analysis for matched case-control studies. Biometrics. 1991 Mar; 47(1): 87-100; and, Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med. 1991 Dec 1; 115(11): 901-5.), should be presented for retrospective studies where unmeasured independent variables may have potentially influenced the results.

    Additional references that may be useful in regard to the description of the methods and the presentation of a statistical plan include:

    Bailar JC III, Mosteller F. Guidelines for statistical reporting in articles for medical journals: amplifications and explanations. Ann Intern Med 1988; 108: 266-73.

    Altman DG, Machin D, Bryant TN, Gardner MJ (eds). Statistics with Confidence. 2nd edition. London: BMJ Books, 2000, pp. 104-6.

    Malay DS. Some thoughts about data type, distribution, and statistical significance. J Foot Ankle Surg 45: 57-9, 2006.

    Malay DS. Levels of clinical evidence. J Foot Ankle Surg 46: 63-4, 2007.

    Results: The results section should provide quantitative information about the data collected, in the form of descriptive and inferential statistics.

    · Relevant information on the study population includes demographic information for each subgroup (control group and study groups), exclusions and attrition. Inferential statistics should be used to compare groups using appropriate statistical tests based on the size of the study population, type of variables under study (discrete vs. categorical), and the distribution of the data collected.

    · Quantitative information should be summarized in the text, and readers should be referred to relevant tables for more detailed information. As a rule, a minimum of three results tables should be presented, and designated Tables 1, 2, and 3. Table 1 typically depicts the baseline demographic characteristics of the sample population, often categorizing the patients/participants by intervention or outcome, and showing whether or not statistically significant differences existed between the groups. For randomized controlled trials, it is not necessary to depict statistically significant differences at baseline, since randomization distributes the characteristics by chance. Table 2 generally depicts the results of the univariate analyses, and Table 3 generally depicts the results of the multiple variable analyses.

    · For randomized controlled trials, the first figure should be the study flow chart.

    · For meta-analyses and systematic reviews, a Christmas tree diagram should be included.

    · Consistency and clarity is required when reporting results. As a rule, report means with standard deviations (using the ± symbol) and medians with the range (either minimum and maximum or 25th and 75th percentiles), and always report the proportion of the whole when presenting count data (for instance, “…4 (3.25%) displayed wound dehiscence…”), and report calculations to 2 decimal places.

    · It is also crucial that authors remain clear and consistent when they report denominators, with a particular emphasis on clarity in regard to the number of patients versus the number of feet or ankles or extremities, since these numbers vary based on unilateral versus bilateral cases.

    Discussion: The discussion section offers the authors' interpretation of the results of their investigation. Authors should consider how their results fit into the general state of knowledge on the subject, as well as their clinical relevance. In addition, authors should acknowledge the limitations of their investigation that may have introduced bias, and they should discuss how the results could have been affected by bias.

    Finally, suggestions for clinical applications and/or further research may be appropriate. Do not include a separate “Conclusion” subsection, as the final paragraph of the discussion should describe the authors’ conclusions (and the paragraph can start with a sentence that states: “In conclusion, we found…” or something to this effect).

    Acknowledgment: Acknowledgments should be made to those who have informally contributed their expertise or assisted in the investigation, rather than to those who have contributed to the manuscript while performing the role of their regular occupation.

    References: References are cited in the body of the text by means of numeric citations listed parenthetically in the appropriate sentence, prior to the end of the sentence (usually just before the period ending the sentence). Reference citations are to appear in sequential numeric order, beginning with the number “1” and continuing in order the first time that a particular reference is cited, until the last citation is noted. In other words, supply references numbered in the exact order they appear in the text (not alphabetically).

    Do not use superscripts, and do not submit a document with endnotes embedded via software algorithms (macros) that link items on the reference page to the in-text citation. If you use such macros to write your paper, please disable the macro, or convert the references cited to text only, prior to submitting your manuscript. This is important because embedded macros impede the editorial process, and greatly slow down the turnaround time related to reviewing and editing a manuscript.

    Always list all authors, and do not use "et al" when listing your references. The term “et al” may be used in the body of the text; however, it is generally reserved for mentioning papers written by more than three authors. Textbook references must include the specific page or pages used. Web site references must include the date when the site was last accessed.

    Examples of reference citations include:

    Journal Article
    1. Mendicino RW, Orsini RC, Whitman SE, Cantanzariti AR. Fibular grove deepening for recurrent peroneal subluxation. J Foot Ankle Surg 40:252-263, 2001.

    Textbook
    2. Trevino SG. Disorders of the hallucal sesamoids. In Foot and Ankle Disorders, pp 379-398, edited by MS Myerson, WB Saunders, Philadelphia, 2000.

    Electronic Version of Print Journal
    3. Gardner MJ, Boraiah S, Hentel KD, Helfet DL, Lorich DG. The hyperplantarflexion ankle fracture variant. J Foot Ankle Surg [serial on the Internet] 46:256-60, 2007. Available at: http://www.jfas.org/issues/contents.

    Web Page
    4. Clinical Practice Guideline Heel Pain Panel. Diagnosis and Treatment of Heel Pain. American College of Foot and Ankle Surgeons Web site. September/October 2001. Available at: http://www.acfas.org/pubresearch/cpg/heelpain-cpg.htm. Accessed July 20, 2007.

    Personal Communication
    NEVER IN REFERENCE LIST. ONLY IN TEXT. (John A. Ruch, DPM; personal communication, dd/mm/yyyy)

    Results
    Results should be clear and concise.

    Discussion
    This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

    Tips, Quips, and Pearls Follow These Headings: Introduction, Technique, Discussion

    Essential title page information

    Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
    Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
    Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.
    Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

    Appropriate trademark symbols must be used for all proprietary information.

    Abstract

    The abstract summarizes the contents of the article on a page separate from the title and manuscript. 250 words or less. No subheadings. Research Article: Introduce research problem, explain methods, summarize results, and provied a conclusion. Case Study: State the condition of interest and summarize the specific clinical situation, the uniqueness, or the rarity of the diagnosis or the novelty of an intervention, and a statement regarding the clinical significance of the case.

    Level of Clinical Evidence

    Immediately following the Abstract, designate the Level of Clinical Evidence.

    Keywords

    Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

    Therapeutic
    Level 1: High-quality RCT with or without statistically significant difference and narrow confidence intervals; Systematic review of homogenous Level 1 RCTs. Level 2: Flawed RCT (<80% follow-up, improper randomization, no blinding, no ITT analysis; Prospective comparative study; Systematic review of Level 2 studies or Level 1 study with inconsistent results. Level 3: Case-control study, Retrospective comparative study, Systematic review of Level 3 studies. Level 4: Case report or series (N < 30). Level 5: Expert opinion.

    Prognostic
    Level 1: High quality prospective study (patients enrolled at same time in disease, less than 80% follow-up); Systematic review of Level 1 studies. Level 2: Retrospective study; Untreated controls from a RCT; Flawed prospective study (patients enrolled at different points in their disease, less than 80% follow-up); Systematic review of Level 2 studies. Level 3: Case-control study. Level 4: Case report or series (N < 30). Level 5: Expert opinion.

    Diagnostic
    Level 1: Testing of established diagnostic criteria in series of consecutive patients with universally applied “gold” standard; Systematic review of Level 1 studies. Level 2: Development of diagnostic criteria in series of consecutive patients with universally applied “gold” standard; Systematic review of Level 2 studies. Level 3: Study of nonconsecutive patients without consistently applied “gold” standard; Systematic review of Level 3 studies. Level 4: Case-control study; Poor reference standard. Level 5: Expert opinion.

    Economic and Decision Analysis
    Level 1: Sensible costs and alternatives; values obtained from many studies; multiway sensitivity analyses; Systematic review of Level 1 studies. Level 2: Sensible costs and alternatives, values obtained from limited studies, multiway sensitivity analyses; Systematic review of Level 2 studies. Level 3: Analysis based on limited alternatives and costs, poor estimates; Systematic review of Level 3 studies. Level 4: No sensitivity analysis. Level 5: Expert opinion.

    Note
    Readers must completely assess and critically appraise the quality of individual studies. A systematic review combines results from 2 or more homogeneous studies (a meta-analysis is a quantitative systematic review that pools results from homogeneous studies). High-quality studies show consistent results and uphold the building blocks of clinical evidence (randomized allocation of treatment, blind outcomes assessment, intention to treat analysis, all reasonable clinically relevant independent variables considered). Prospective studies start before the first participant (patient) enrolled, and are suitable for identification of the incidence of an outcome and calculation of relative risk. Comparative studies compare patients treated one way with those treated in another way. Retrospective studies start after the first participant (patient) enrolled, and are suitable for identification of the incidence of an outcome and calculation of relative risk. Case-control studies entail patients identified for inclusion on the basis of their outcome, called "cases," that are compared with those who did not have the outcome, called "controls;" are retrospective and suitable for identification of differences in exposures and calculation of relative odds. Case series involve patients treated one way with no comparison group.

    Abbreviations

    Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

    · If a proper or proprietary name entails the use of an abbreviation, only then can it be used in the Title, Abstract or Key Words sections.

    ·  Abbreviations can be used in the Introduction, as well as any area of the manuscript thereafter.

    · Abbreviations are not to be used unless the term has first been spelled in full, and the abbreviation noted in parentheses immediately following the initial use of the full term. For example: “…deep peroneal nerve (DPN).”

    · Abbreviations that are part of a proprietary name are to be used in accordance with the guidelines noted for registered trademarks and copyrights.

    Acknowledgements

    Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

    Units

    Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

    Artwork

    Electronic artwork
    General points
    • Make sure you use uniform lettering and sizing of your original artwork.
    • Embed the used fonts if the application provides that option.
    • Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
    • Number the illustrations according to their sequence in the text.
    • Use a logical naming convention for your artwork files.
    • Provide captions to illustrations separately.
    • Size the illustrations close to the desired dimensions of the printed version.
    • Submit each illustration as a separate file.
    A detailed guide on electronic artwork is available on our website:
    http://www.elsevier.com/artworkinstructions
    You are urged to visit this site; some excerpts from the detailed information are given here.
    Formats
    If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
    Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
    EPS (or PDF): Vector drawings, embed all used fonts.
    TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
    TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
    TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.
    Please do not:
    • Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
    • Supply files that are too low in resolution;
    • Submit graphics that are disproportionately large for the content.

    · Figures and their accompanying legends should be able to stand alone, communicating the meaning of the information without reference to the main text (as described above for tables).

    · In the text, figures should be cited using parentheses about the figure-reference being cited. For example: (Figure 1).

    · Each figure should be titled, and accompanied by a figure legend, and submitted in consecutive order as an independent file following the manuscript and tables.

    · The figure title should be formatted as in the following example: “Figure 1 The gastrocnemius recession.”

    ·  In the title of the figure, the term “Figure” and the number designation should be bold font, with the title following in regular (not bold) font, for example: “Figure 1 The gastrocnemius recession.” Furthermore, for histograms and graphic plots, the sample size should be clearly stated at the end of the title, so that readers do not need to resort to reading the Materials and Methods section in order to understand the figure. For example: “Figure 1 Age distribution for gastrocnemius recession cases (N = 58 procedures in 55 patients).” Please note that it is preferable to specify the number of feet, or ankles, and the number of patients (if some of the cases were bilateral).

    · Do not use abbreviations in either the figure title or the figure legend, unless the abbreviation is defined in the legend.

    · Abbreviations or footnotes should be explained in lower case alphabetical superscripts in the legend beneath the figure.

    · Each figure title and legend should be submitted in consecutive order on a separate page (file), or included in the body of the manuscript under the heading “Figures and Legends” (preferable). The actual figures must be submitted as separate files, in consecutive order; whereas the titles and legends are to be included as noted above at the end of the manuscript.

    · Images should be provided in TIF, GIF or EPS format, per the instructions for online submission at http://ees.elsevier.com/jfas.

    · Radiographic images should be submitted in grayscale format, with the projection spelled out in full (anteroposterior, lateral, medial oblique, Isherwood, etc.).

    · Black and white line drawings are acceptable only if they are of professional quality.

    · All figures must be original, unless indicated otherwise.

    · Figures previously published in other sources should be accompanied by a letter from that publishing company and author, granting permission for their use.

    · Illustrations and figures will not be returned to the authors.

    Color artwork
    Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.

    Figure captions
    Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

    Tables

    Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

    · Black and white lines and text are preferred. The “insert table” function of the toolbar of most word processors works well for this.

    · Tables and their accompanying legends should be able to stand alone, communicating the meaning of the information without reference to the main text.

    ·  In the text, tables are cited using parentheses about the table-reference being cited. For example: (Table 1).

    · Each table should be titled, and accompanied by a legend beneath the table.

    · The table title should be formatted as in the following example: “Table 1 The dataset”

    · In the title of the table, the term “Table” and the number designation should be bold font, with the title following in regular (not bold) font. Furthermore, the sample size should be clearly stated in the title, so that readers do not need to resort to reading the Materials and Methods section in order to understand the table. For example: “Table 1 Surgical cases (N = 58 feet in 55 patients).” Please note that it is preferable to specify the number of feet, or ankles, and the number of patients (if some of the cases were bilateral).

    · Do not use abbreviations in either the title or the table legend, unless the abbreviation is defined in the legend.

    · Abbreviations or footnotes should be explained in lower case alphabetical superscripts in the legend beneath the table.

    · Each table (with title and legend) may be submitted in consecutive order on a separate page (file), or included in the body of the manuscript under the heading “Tables” (preferable).

    · Tables previously published in other sources should be accompanied by a letter from that publishing company and author, granting permission for their use.

    References

    Always list all authors in the Reference list; "et al" can be used in the text only.

    Citation in text
    Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

    Reference links
    Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

    Web references
    As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

    Reference style
    Journal article: Wang L, Gui J, Gao F, Zhong Y, Jiang Y, Xu Y, Shen H. Modified posterior portals for hindfoot arthroscopy. Arthroscopy 23:1116–1123, 2007. Book chapter: Canale ST, Beaty JH. Congenital clubfoot (talipes equinovarus). In: Campbell's Operative Orthopaedics, ed 11, Elsevier, Philadelphia, 2007. Website: Clinical Practice Guideline Heel Pain Panel. Diagnosis and Treatment of Heel Pain. American College of Foot and Ankle Surgeons. Available at: http://www.acfas.org/pubresearch/cpg/heelpain-cpg.htm. Accessed July 20, 2007.

    Journal abbreviations source
    Journal names should be abbreviated according to the List of Title Word Abbreviations: http://www.issn.org/services/online-services/access-to-the-ltwa/.

    Video data

    Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

    Supplementary data

    Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.

    Submission checklist

    The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.
    Ensure that the following items are present:
    One author has been designated as the corresponding author with contact details:
    • E-mail address
    • Full postal address
    • Phone numbers
    All necessary files have been uploaded, and contain:
    • Keywords
    • All figure captions
    • All tables (including title, description, footnotes)
    Further considerations
    • Manuscript has been 'spell-checked' and 'grammar-checked'
    • References are in the correct format for this journal
    • All references mentioned in the Reference list are cited in the text, and vice versa
    • Permission has been obtained for use of copyrighted material from other sources (including the Web)
    • Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
    • If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes
    For any further information please visit our customer support site at http://support.elsevier.com.

    Use of the Digital Object Identifier

    The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B):
    http://dx.doi.org/10.1016/j.physletb.2010.09.059
    When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

    Proofs

    One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 9 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html.
    If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.



    You can track your submitted article at http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/. You can track your accepted article at http://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.

    Authors with questions are instructed to review the frequently asked questions and/or employ the e-submission support or help functions embedded in the electronic manuscript submission system. Those with other specific questions related to content or the status of peer review and editorial consideration of a manuscript should inquire at authorquestionjfas@gmail.com. Authors with questions must include the following information: (1) manuscript number, (2) corresponding author first and last names, (3) manuscript title.

Advertisement

advert image